EP1003538B1 - Verwendung von polygonatum extrakten, um die hautelastin-synthese zu stimulieren - Google Patents

Verwendung von polygonatum extrakten, um die hautelastin-synthese zu stimulieren Download PDF

Info

Publication number
EP1003538B1
EP1003538B1 EP98942719A EP98942719A EP1003538B1 EP 1003538 B1 EP1003538 B1 EP 1003538B1 EP 98942719 A EP98942719 A EP 98942719A EP 98942719 A EP98942719 A EP 98942719A EP 1003538 B1 EP1003538 B1 EP 1003538B1
Authority
EP
European Patent Office
Prior art keywords
polygonatum
extract
use according
collagen
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP98942719A
Other languages
English (en)
French (fr)
Other versions
EP1003538A1 (de
Inventor
Alain Meybeck
Frédéric Bonte
Marc Dumas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LVMH Recherche GIE
Original Assignee
LVMH Recherche GIE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LVMH Recherche GIE filed Critical LVMH Recherche GIE
Publication of EP1003538A1 publication Critical patent/EP1003538A1/de
Application granted granted Critical
Publication of EP1003538B1 publication Critical patent/EP1003538B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8969—Polygonatum (Solomon's seal)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/002—Aftershave preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to the use of extracts of Polygonatum to stimulate the synthesis of skin elastin.
  • the rhizomes of Polygonatum and, in particular of Polygonatum sibiricum Redoute, of Polygonatum cynonema Hua or of Polygonatum kingianum Coll. and Hemsl. (Liliaceae) are used in traditional medicine Chinese under the name of Huang Jing (Chinese Medical Material - B. Auteroche, M. Auteroche, M. Demont - Maloine 1992, p. 620).
  • the main indications Polygonatum rhizomes are for the treatment of dry cough due to deficiency of the lung, to tone the kidneys or to treat deficiencies of the spleen or stomach.
  • Polygonatum extracts could stimulate synthesis of elastin by fibroblasts of the dermis, in particular fibroblasts of the dermis human.
  • the elastic fibers form a network which contributes to the elasticity of the skin and therefore to its tone and firmness.
  • Elastin is the major component of these fibers. She is initially synthesized by fibroblasts in the form of a soluble polypeptide of 70 kDa. tropoelastin. The formation of microfibrils is then carried out by links intramoleculars called desmosines between lysine residues of chains polypeptide. These bonds give elastin great insolubility.
  • the present invention aims to solve the new technical problem consisting in providing a solution allowing improve skin elasticity by promoting elastin synthesis, according to a simple design solution, easily usable on an industrial scale while allowing cosmetic or pharmaceutical use, especially dermatological.
  • the present invention relates to the use of an extract of Polygonatum as a cosmetic agent intended to stimulate the synthesis of elastin by fibroblasts of the dermis.
  • the stimulation of the synthesis of elastin has for result of improving skin elasticity and tone or promoting skin firming.
  • the extract will advantageously be chosen from among the extracts from rhizomes of Polygonatum kingianum, P. sibiricum, P. cyrtonema, from P. zanlanscianense and other rhizome extracts from Polygonatum known by the Chinese name of Huan Jing.
  • the above-mentioned Polygonatum extract can be used as well curative as preventive, to correct or prevent loss of elasticity, tone or skin firmness, due in particular to aging or exposure to rays ultraviolet.
  • the extract of Polygonatum is an extract from the ground rhizomes.
  • the extract is advantageously obtained by a process using a step of extracting the plant material with a polar solvent or a mixture polar solvents.
  • the extraction is carried out by means of a solvent chosen from the group consisting of water, the alcohols comprising preferably from 1 to 4 carbon atoms, and mixed solvents based on mixtures any of the above solvents.
  • an alcohol such as methanol, ethanol, propanol, isopropanol, propylene glycol or butylene glycol, or a mixture of these alcohols or a hydro-alcoholic mixture.
  • solvent chosen from the group consisting of methanol, ethanol, 1,3-butylene glycol and mixtures of these solvents with each other or with water.
  • the well-known conventional extraction procedures of those skilled in the art can be used.
  • the extraction can be carried out on the ground plant material.
  • the extraction is carried out from rhizomes.
  • the ground vegetable material is introduced into the solvent extraction, preferably consisting of the solvent or mixture of solvents polar above.
  • the extraction can be repeated several times until depletion of plant material, in accordance with well known methods of one skilled in the art.
  • the extraction can be carried out at room temperature, or at hot and in particular at the reflux of the solvent.
  • the proportion by weight between the material vegetable and the solvent can vary within wide limits. Specifically, it can be between 1: 5 and 1: 100, and preferably between 1: 10 and 1: 20.
  • the extract of Polygonatum supra is used topically at a concentration included between 0.001% and 10% relative to the total weight of a composition containing it in a suitable excipient, vehicle or support, preferably cosmetically acceptable.
  • a preferred concentration is between 0.01 and 2% by weight relative to the total weight of the composition containing it.
  • the extract of Polygonatum according to the invention is used in combination with an amount effective of an active ingredient stimulating the synthesis of the components of the matrix extracellular dermis, including collagen, in particular collagen 1 and collagen III, and glycosaminoglycans, in particular hyaluronic acid.
  • an active principle stimulating the synthesis of collagen in particular collagen I and collagen III, madecassoside, an extract of Centella asiatica, or an extract of ginseng, in particular an extract containing ginsenoside R, is used. o , said active principle being at a concentration of between 0.01% and 5% by weight relative to the total weight of the final composition.
  • a plant extract such as an extract of Filicium decipiens, in particular an extract of root bark from this plant, described in the application for French patent 95 07708, or an extract of Eryobotria japonica described in the French patent application 96. 00018, or a growth factor, in particular PDGF (platelet derived growth factor), growth factor derived from platelets.
  • PDGF platelet derived growth factor
  • the extract of Polygonatum supra is used in combination with a vitamin, in particular vitamin A, its palmitic, propionic or acetic ester or vitamin E and its derivatives. in particular its phosphate, at a concentration between 0.0001 and 10%, preferably between 0.0001 and 5%, by weight relative to the weight total of the composition.
  • a vitamin in particular vitamin A, its palmitic, propionic or acetic ester or vitamin E and its derivatives. in particular its phosphate, at a concentration between 0.0001 and 10%, preferably between 0.0001 and 5%, by weight relative to the weight total of the composition.
  • the present invention also covers a method of treatment, cosmetic of the skin, intended for prevent or correct a loss of elasticity, tone or firmness in the skin, characterized in that it comprises application to the areas of the skin to be treated an effective amount of an extract of Polygonatum, as active ingredient, for stimulate the synthesis of elastin by fibroblasts, said active principle being incorporated in a cosmetically acceptable excipient.
  • rhizome extract from Polygonatum kingianum, P. sibiricum, P. cyrtonema, from P. zanlanscianense, or any other rhizome extract from Polygonatum known by the Chinese name of Huang Jing.
  • the methanolic phase is allowed to cool to temperature room, then filter.
  • the solid residue is extracted again from the same way with 1 liter of methanol.
  • Example 2 The procedure is as in Example 1, except that the plant material is from the rhizome of Polygonatum sibiricum and the solvent is a mixture ethanol-water 75:25 by volume.
  • the extract obtained after evaporation of the solvent in a rotary flask is lyophilized to obtain a dry powdery product.
  • the culture is continued for 48 h.
  • the dose is applied to the culture supernatants elastin secreted by an ELISA method derived from that used for the assay of collagen as described by Dumas M. et al. in the publication cited above, except that a polyclonal anti-elastin antibody commercial human was used in place of the anti-collagen polyclonal antibody 1 and III human.
  • This assay is naturally also carried out on control cultures, do not receiving no product to test.
  • a standard range made from commercially soluble elastin converts optical density (OD) values to nanograms of elastin obtained from culture supernatants.
  • a protein dosage cells is carried out on fibroblast cultures, after elimination of the supernatant, in order to reduce the quantity of elastin dosed to a fixed quantity of cellular proteins.
  • the assay is carried out using the BCA-1 kit (Bicinchoninic acid kit, marketed by Sigma, France) after dissolution of the cell carpet with 0.1 N soda
  • Tables 1 and 2 report the test results with the Polygonatum extract obtained according to Example 1 at different concentrations on the fibroblast cultures of the two donors.
  • Activity of an extract of Polygonatum on the synthesis of elastin (fibroblasts of the face of a 47 year old woman)
  • Activity of an extract of Polygonatum on the synthesis of elastin (fibroblasts of the face of a 49 year old woman)
  • the Polygonatum extract stimulates strongly elastin synthesis. This stimulation increases with concentration of the product tested.
  • compositions are expressed below in percentages by weight.
  • Liposome gel for facial care Polygonatum extract according to Example 1 0.2 soy lecithin 1 hyaluronic acid in 1% aqueous solution 1 Carbopol® 941 1.25 water + preservative + triethanolamine qs 100.
  • this skincare product improves and maintains firmness and tone of facial skin and reduces wrinkles and fine lines.
  • This emulsion is applied morning and evening and restores elasticity to the face. which then has a good tone and a firmer appearance.
  • Fluid emulsion for the body vegetable oil 2 caprylic / capric triglyceride 5 vitamin E phosphate 0.3 carbomer 0.5 xanthan gum 0.20 hyaluronic acid 1% solution 1 Polygonatum extract according to example 1 0.2 extract of Eriobotrya japonica 0.1 Centella asiatica extract 0.1 green tea extract 0.05 water + preservative + cooling agent + fragrance qs 100
  • Tonic facial lotion Lotion A dry hydroethanolic extract of Polygonatum according to Example 2 .. 0.3 extract of Eriobotrya japonica 1 ginsenoside R o 0.4 1% aqueous solution of hyaluronic acid 1 glycerol 2 water + preservative qs 100.
  • This tonic lotion can be used by women after make-up removal or by men after shaving.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Claims (11)

  1. Kosmetische Verwendung eines Polygonatumextraktes als Mittel zur Stimulation der Elastinsynthese durch die Fibroblasten der Lederhaut, um die Hautelastizität und -spannkraft zu verbessern und um die Festigung der Haut zu begünstigen, wobei das Mittel einer kosmetischen Zusammensetzung beigemengt ist, welche ein kosmetisch akzeptables Vehikel enthält.
  2. Verwendung nach Anspruch 1, dadurch gekennzeichnet, dass der Polygonatumextrakt ausgewählt ist unter den Polygonatum kingianum-, P. sibiricum-, P. cyrtonema-, P. zanlanscianense-Rhizom-Extrakten und den anderen Polygonatum-Rhizom-Extrakten, welche unter dem chinesischen Namen Huang Jing bekannt sind.
  3. Verwendung nach einem der Ansprüche 1 oder 2, dadurch gekennzeichnet, dass der Extrakt durch ein Verfahren erhalten wird, das wenigstens einen Schritt zum Extrahieren des Pflanzenstoffes durch ein polares Lösungsmittel oder eine Mischung aus polaren Lösungsmitteln vollzieht.
  4. Verwendung nach Anspruch 3, dadurch gekennzeichnet, dass das polare Lösungsmittel oder die Mischung aus polaren Lösungsmitteln ausgewählt ist aus der Gruppe bestehend aus Wasser, Alkoholen mit vorzugsweise 1 bis 4 Kohlenstoffatomen, vorzugsweise Methanol, Ethanol, Propanol, Isopropanol, Propylenglykol oder Butylenglykol und gemischten Lösungsmitteln auf der Basis von beliebigen Mischungen dieser Lösungsmittel.
  5. Verwendung nach Anspruch 3 oder 4, dadurch gekennzeichnet, dass das Lösungsmittel oder die Mischung aus polaren Lösungsmitteln ausgewählt ist aus der Gruppe bestehend aus Methanol, Ethanol, 1,3-Butylenglykol und Mischungen dieser Lösungsmittel miteinander oder mit Wasser.
  6. Verwendung nach einem der Ansprüche 1 à 5, dadurch gekennzeichnet, dass der Polygonatumextrakt örtlich in einer Konzentration zwischen 0,001 Gew.-% und 10 Gew.-% gegenüber dem Gesamtgewicht einer Zusammensetzung verwendet wird, die ihn in einem geeigneten, insbesondere kosmetisch akzeptablen Bindemittel, Vehikel oder Träger enthält.
  7. Verwendung nach Anspruch 6, dadurch gekennzeichnet, dass der vorgenannte Polygonatumextrakt in einer Konzentration zwischen 0,01 und 2 Gew.-% gegenüber dem Gesamtgewicht der genannten Zusammensetzung verwendet wird.
  8. Verwendung nach einem der Ansprüche 1 bis 7, dadurch gekennzeichnet, dass der vorgenannte Polygonatumextrakt in Verbindung mit einer wirksamen Menge eines aktiven Bestandteils verwendet wird, welcher die Synthese der Komponenten der extrazellulären Matrix der Lederhaut, insbesondere das Kollagen, insbesondere Kollagen I und Kollagen III, und die Glykosaminoglykane, insbesondere die Hyaluronsäure, stimuliert.
  9. Verwendung nach Anspruch 8, dadurch gekennzeichnet, dass der vorgenannte Polygonatumextrakt in Verbindung mit einem aktiven, die Synthese des Kollagen, insbesondere des Kollagen I und des Kollagen III stimulierenden Bestandteil verwendet wird, welcher ausgewählt ist aus der Gruppe bestehend aus Madecassosid, einem Centella asiatica-Extrakt und einem Ginseng-Extrakt, insbesondere enthaltend Ginsenosid Ro, in einer Gewichtskonzentration von 0,01 % bis 5%.
  10. Verwendung nach Anspruch 8, dadurch gekennzeichnet, dass der vorgenannte Polygonatumextrakt in Verbindung mit einem aktiven, die Synthese der Glykosaminoglykane stimulierenden Bestandteil verwendet wird, welcher ausgewählt ist aus der Gruppe bestehend aus Filicium decipiens-, Eriobotrya japonica-Extrakten und PDGF (platelet derived growth factor).
  11. Verwendung nach irgendeinem der Ansprüche 1 bis 10, dadurch gekennzeichnet, dass der vorgenannte Polygonatumextrakt in Verbindung mit Vitaminen, insbesondere Vitamin A, dessen Palmitin-, Propion- oder Essigester, oder Vitamin E und dessen Derivaten, insbesondere dessen Phosphat, in einer Gewichtskonzentration von 0,0001 bis 10%, verwendet wird.
EP98942719A 1997-08-11 1998-08-10 Verwendung von polygonatum extrakten, um die hautelastin-synthese zu stimulieren Expired - Lifetime EP1003538B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9710258 1997-08-11
FR9710258A FR2767059B1 (fr) 1997-08-11 1997-08-11 Utilisation d'extraits de polygonatum pour stimuler la synthese de l'elastine cutanee
PCT/FR1998/001784 WO1999007397A1 (fr) 1997-08-11 1998-08-10 Utilisation d'extraits de polygonatum pour stimuler la synthese de l'elastine cutanee

Publications (2)

Publication Number Publication Date
EP1003538A1 EP1003538A1 (de) 2000-05-31
EP1003538B1 true EP1003538B1 (de) 2004-02-18

Family

ID=9510220

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98942719A Expired - Lifetime EP1003538B1 (de) 1997-08-11 1998-08-10 Verwendung von polygonatum extrakten, um die hautelastin-synthese zu stimulieren

Country Status (6)

Country Link
EP (1) EP1003538B1 (de)
JP (1) JP2001513509A (de)
DE (1) DE69821769T2 (de)
ES (1) ES2216303T3 (de)
FR (1) FR2767059B1 (de)
WO (1) WO1999007397A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003212749A (ja) * 2002-01-16 2003-07-30 Noevir Co Ltd ＡＧＥｓ生成抑制剤及びそれを含有する皮膚外用剤
JP2003261432A (ja) * 2002-03-07 2003-09-16 Noevir Co Ltd 皮膚外用剤
JP4641419B2 (ja) * 2002-12-02 2011-03-02 ポーラ化成工業株式会社 メラノサイトのデンドライト伸長抑制剤及びそれを含有する皮膚外用剤
JP2005247826A (ja) * 2004-02-04 2005-09-15 Kose Corp デコリン産生促進剤及びそれを含有する皮膚外用剤
DE102005012554A1 (de) * 2005-03-16 2006-09-28 Beiersdorf Ag Kosmetische Zubereitung mit Hyaluronsäure
EP1951762B1 (de) * 2005-10-03 2018-02-07 PINSKY, Mark A. Zusammensetzungen und verfahren zur verbesserten hautpflege
JP5010879B2 (ja) * 2006-09-07 2012-08-29 常盤薬品工業株式会社 液剤組成物
JP2011102275A (ja) * 2009-11-11 2011-05-26 Shiseido Co Ltd Ｔｉｅ２活性化剤、血管の成熟化、正常化又は安定化剤、リンパ管安定化剤並びにしわ防止・改善剤及びむくみ改善・予防剤
WO2012101741A1 (ja) * 2011-01-24 2012-08-02 株式会社資生堂 Tie2活性化剤、血管の成熟化、正常化又は安定化剤、リンパ管安定化剤並びにしわ防止・改善剤及びむくみ改善・予防剤
CN102755266A (zh) * 2011-04-26 2012-10-31 上海家化联合股份有限公司 一种中草药提取物及其制备和应用
JP2018000051A (ja) * 2016-06-29 2018-01-11 政浩 深堀 ナルコユリ又はオオナルコユリを原料とする粉末飲料及び液体飲料
KR102121301B1 (ko) * 2018-03-30 2020-06-11 농업회사법인(주)제주우다 마유를 이용한 마스크팩 조성물 및 이의 제조방법
KR102042799B1 (ko) * 2018-03-30 2019-11-08 농업회사법인(주)제주우다 액상 마유의 제조방법
KR102121305B1 (ko) * 2018-03-30 2020-06-11 김영선 고상 마유의 제조방법
CN110623890A (zh) * 2018-06-21 2019-12-31 伽蓝（集团）股份有限公司 滇黄精提取物的应用
KR102079263B1 (ko) * 2018-08-23 2020-02-19 제주대학교 산학협력단 마유의 정제방법 및 그로부터 수득되는 정제마유를 이용하는 화장료 조성물
KR102303079B1 (ko) * 2019-07-11 2021-09-16 제주대학교 산학협력단 마유 리포좀을 함유한 탈모방지 및 발모촉진용 조성물
CN113368530A (zh) * 2021-06-07 2021-09-10 上海应用技术大学 一种多花黄精提取液的提取方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2969274B2 (ja) * 1989-12-21 1999-11-02 株式会社資生堂 肌荒れ防止改善剤
JP3055826B2 (ja) * 1991-03-28 2000-06-26 株式会社コーセー 皮膚化粧料
JP3536111B2 (ja) * 1992-06-29 2004-06-07 株式会社ナリス化粧品 ムコ多糖類断片化抑制剤および化粧料
JPH08283172A (ja) * 1995-04-14 1996-10-29 Kose Corp 活性酸素消去剤及びこれを含有する皮膚外用剤

Also Published As

Publication number Publication date
FR2767059A1 (fr) 1999-02-12
DE69821769T2 (de) 2004-12-02
EP1003538A1 (de) 2000-05-31
FR2767059B1 (fr) 2000-03-24
WO1999007397A1 (fr) 1999-02-18
JP2001513509A (ja) 2001-09-04
ES2216303T3 (es) 2004-10-16
DE69821769D1 (de) 2004-03-25

Similar Documents

Publication Publication Date Title
EP1003538B1 (de) Verwendung von polygonatum extrakten, um die hautelastin-synthese zu stimulieren
BE1009858A5 (fr) Utilisation de la vitamine c ou de ses derives ou analogues pour stimuler la synthese de l'elastine cutanee.
EP1001740B1 (de) Verwendung von ginsenoside rb1 zur stimulierung der elastinsynthese
FR3057462A1 (fr) Extrait d'anigozanthos flavidus pour son utilisation cosmetique
FR2929511A1 (fr) Nouveau principe actif stimulant la proliferation et/ou l'activite des fibroblastes.
WO2019025725A1 (fr) Utilisation d'un extrait de péricarpe de nephelium lappaceum pour hydrater la peau et/ou les muqueuses
WO2012172199A1 (fr) Composition a base de camellia japonica et polygonum hydropiper pour protection de la peau
JP2023052050A (ja) 皮膚及び／又は粘膜の硬さを増大させるためのネフェリウム・ラッパセウム（Ｎｅｐｈｅｌｉｕｍ ｌａｐｐａｃｅｕｍ）抽出物の使用
FR3011469A1 (fr) Utilisation cosmetique et/ou dermatologique d'un extrait d'hamamelis virginiana
EP0946138B1 (de) Verwendung eines potentilla erecta extraktes im kosmetischen und pharmazeutischen gebiet
FR2973230A1 (fr) Utilisation de gingerone ou de ses derives pour diminuer ou retarder les signes du vieillissement de la peau
FR2826579A1 (fr) Composition cosmetique contenant au moins une huile extraite de graines de cucurbitacees, son utilisation cosmetique, therapeutique et alimentaire
FR2783425A1 (fr) Extrait de myrte titre en myrtucommulone b', son procede de preparation et son application en dermatologie et en cosmetologie
FR3049859A1 (fr) Utilisation cosmetique d'un extrait de khaya senegalensis
EP0809484B1 (de) Bertholletia enthaltende kosmetische oder pharmazeutische,insbesondere dermatologische zusammensetzung
EP3801778B1 (de) Verwendung eines bixa-orellana-extraktes
US5807555A (en) Skin treatments with Smelophyllum capense extracts
FR3091162A1 (fr) Utilisation cosmétique et/ou nutraceutique d'un extrait d'écorce d'Eperua falcata
FR3010314A1 (fr) Utilisation cosmetique ou dermatologique d'un extrait de tapirira guyanensis
WO2018115733A1 (fr) Utilisation cosmétique d'un extrait de corchorus olitorius
FR3061016A1 (fr) Utilisation cosmetique d'un extrait de mitracarpus scaber comme agent anti-age
FR2828401A1 (fr) Composition cosmetique ou dermatologique comprenant une association entre l'igf1 et/ou un compose mimetique de l'igf1, et l'acide ascorbique et/ou au moins l'un de ses derives
KR20170025360A (ko) 피부 개선용 조성물

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000225

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE ES FR GB IT

17Q First examination report despatched

Effective date: 20020320

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): DE ES FR GB IT

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REF Corresponds to:

Ref document number: 69821769

Country of ref document: DE

Date of ref document: 20040325

Kind code of ref document: P

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 20040423

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2216303

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20041119

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20070809

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20070824

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20070810

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20070816

Year of fee payment: 10

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20080810

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080810

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090303

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20080811

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080810

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080811

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20150630

Year of fee payment: 18

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20170428

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160831